Cargando…
Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic
Oligodendrocyte death contributes to the pathogenesis of the inflammatory demyelinating disease multiple sclerosis (MS). Nevertheless, current MS therapies are mainly immunomodulatory and have demonstrated limited ability to inhibit MS progression. Protection of oligodendrocytes is therefore a desir...
Autores principales: | Way, Sharon W., Podojil, Joseph R., Clayton, Benjamin L., Zaremba, Anita, Collins, Tassie L., Kunjamma, Rejani B., Robinson, Andrew P., Brugarolas, Pedro, Miller, Robert H., Miller, Stephen D., Popko, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Pub. Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360920/ https://www.ncbi.nlm.nih.gov/pubmed/25766071 http://dx.doi.org/10.1038/ncomms7532 |
Ejemplares similares
-
Insights into the mechanism of oligodendrocyte protection and remyelination enhancement by the integrated stress response
por: Chen, Yanan, et al.
Publicado: (2023) -
Prolonging the integrated stress response enhances CNS remyelination in an inflammatory environment
por: Chen, Yanan, et al.
Publicado: (2021) -
Remyelination therapy goes to trial for multiple sclerosis
por: Brugarolas, Pedro, et al.
Publicado: (2014) -
Phosphorylation State of ZFP24 Controls Oligodendrocyte Differentiation
por: Elbaz, Benayahu, et al.
Publicado: (2018) -
Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
por: Titus, Haley E., et al.
Publicado: (2020)